2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.16 Curt

PP01.16 Curt - Poster

Pdf Summary

Small-cell lung cancer (SCLC) is a highly aggressive form of lung cancer often associated with tobacco use. Veterans, who have higher rates of tobacco use and exposure to carcinogens due to their military service, are at increased risk for SCLC. Lurbinectedin, an FDA-approved drug for SCLC, has shown promise in clinical trials, especially in patients with a longer interval between platinum therapies. However, its efficacy in Veterans, who may have different clinical profiles and exposure histories, is not well understood. A retrospective study of 415 Veterans treated with lurbinectedin revealed a median overall survival of 4.8 months, shorter than in previous trials. Factors like brain metastasis and prior immunotherapy did not significantly impact survival outcomes. A chemotherapy-free interval of 90 days was associated with better survival rates. The study highlights the need for further research to improve second-line therapies for SCLC in the Veteran population. Understanding the response to lurbinectedin in Veterans, given their unique risk factors, is crucial for optimizing treatment outcomes.

Keywords

Small-cell lung cancer

SCLC

tobacco use

Veterans

Lurbinectedin

FDA-approved drug

clinical trials

platinum therapies

retrospective study

chemotherapy-free interval